Open the main menu
  • Contact Us
  • Global

News Releases

Text size
view with small font size
view with medium font size
view with large font size

2019 Press Releases

August 23, 2019

Cantargia and BioWa extend ongoing collaboration around the POTELLIGENT® Technology PDF file:New window opens

2018 Press Releases

August 8, 2018

Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc), a POTELLIGENT® antibody for the Treatment of Mycosis Fungoides and Sézary Syndrome PDF file:New window opens

March 22, 2018

Lonza and BioWa Sign POTELLIGENT® CHOK1SVTM Cell Line Technology Licensing Agreement with Tillotts Pharma AG PDF file:New window opens

March 22, 2018

Kyowa Hakko Kirin and BioWa Obtain Successful Settlement of United States Patent Infringement Lawsuit against Aragen Bioscience and Transposagen PDF file:New window opens

2016 Press Releases

October 18, 2016

Kyowa Hakko Kirin and BioWa File Suit in the U.S. to Defend Patent Rights on POTELLIGENT® Technology PDF file:New window opens

April 1, 2016

BioWa Announces Office Relocation to Princeton, NJ and appointment of New President and CEO PDF file:New window opens

January 11, 2016

BioWa opens POTELLIGENT® Technology license to customers for creating POTELLIGENT® cell lines PDF file:New window opens

2015 Press Releases

June 26, 2015

Cantargia licenses BioWa POTELLIGENT® Technology platform for production of lead product candidate PDF file:New window opens

February 16, 2015

Transfer of BioWa's "External Innovation Engine" In-Licensing Activities to Kyowa Hakko Kirin California PDF file:New window opens

2014 Press Releases

March 19, 2014

Lonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with arGEN-X PDF file:New window opens

2013 Press Releases

December 11, 2013

Lonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with MedImmune PDF file:New window opens

July 30, 2013

BioWa and Lonza Sign License Agreements with Pfizer PDF file:New window opens

March 18, 2013

BioWa Relocates to La Jolla, CA PDF file:New window opens

2012 Press Releases

June 15, 2012

Lonza and BioWa Sign License Agreements with FivePrime Therapeutics PDF file:New window opens

2011 Press Releases

July 26, 2011

arGEN-X Announces Non-exclusive License with BioWa for Potelligent Technology PDF file:New window opens

June 2, 2011

ICT and BioWa Announce License for R&D of Therapeutic Antibodies in Cancer PDF file:New window opens

June 1, 2011

Caerus Discovery, LLC – A New Biotechnology Company is Announced PDF file:New window opens

April 6, 2011

Oxford BioTherapeutics Licenses BioWa's POTELLIGENT Technology PDF file:New window opens

February 8, 2011

Kalobios Selects Potelligent CHOK1SV Cell Line for the Research-Development and Manufacture of Humaneered Antibodies PDF file:New window opens

2010 Press Releases

November 15, 2010

BioWa Announces License of POTELLIGENT Technology to Agensys PDF file:New window opens

July 26, 2010

Daiichi Sankyo Selects POTELLIGENT CHOK1SV Cell Line PDF file:New window opens

June 23, 2010

BioWa Announces Expansion of Licenses To Glaxosmithkline PDF file:New window opens

2009 Press Releases

October 21, 2009

BioWa and NKTT Announce Licensing of BioWa Potelligent Tech for use in Antibody R&D PDF file:New window opens

October 12, 2009

Lonza and BioWa Introduce Potent New Cell Line for Recombinant Antibody Production PDF file:New window opens

October 5, 2009

BioWa Announces Second Japanese License of Potelligent® Technology To Otsuka Pharmaceutical PDF file:New window opens

July 29, 2009

BioWa Appoints New Vice President, Corporate Development PDF file:New window opens

July 15, 2009

BioWa Announces License of POTELLIGENT® Technology to Merck KGaA PDF file:New window opens

April 8, 2009

BioWa Announces License of POTELLIGENT® Technology to sanofi aventis PDF file:New window opens

2008 Press Releases

Dec. 8, 2008

BioWa Licenses Potelligent® Technology To Glaxosmithkline For Use In Antibody Development And Commercialization PDF file:New window opens

Oct. 28, 2008

BioWa Announces License Of BioWa's Potelligent® Technology To Kalobios Pharmaceuticals PDF file:New window opens

Oct. 9, 2008

BioWa Licenses Potelligent® Technology To CSL Limited PDF file:New window opens

July 16, 2008

BioWa And Medarex Announce License Of BioWa's Complegent® Technology PDF file:New window opens

June 11, 2008

BioWa Licenses Potelligent® Technology To Major Pharmaceutical Company For Use In Antibody Research And Development PDF file:New window opens

Mar 3, 2008

BioWa Announces Expansion Of License Agreement With Genentech For BioWa's Potelligent® Technology PDF file:New window opens

2007 Press Releases

Dec 12, 2007

BioWa And Lonza Enter Into Strategic Collaboration To Generate Optimized Production Platform For More Potent Antibodies PDF file:New window opens

Oct 24, 2007

BioWa Announces Extended Licensing To Medimmune Of BioWa's Potelligent® Technology For Use In Antibody Research And Development PDF file:New window opens

Oct. 19,2007

BioWa Announces Licensing Of BioWa's Potelligent® Technology By Glaxosmithkline For Use In Antibody Research And Development PDF file:New window opens

July 30,2007

BioWa Introduces Its Second Technology To Dramatically Enhance Antibody Effector Function And The Launch Of AccretamabEplatform PDF file:New window opens

July 23rd, 2007

Phase 1 Interim Clinical Study Data Released Regarding Mild Asthma Anti-Il-5 Receptor Mab

May 30, 2007

BioWa And Takeda Announce Licensing Ofbiowa's Potelligent® Technology For Use In Antibody Research And Development PDF file:New window opens

February 5, 2007

UCB Licenses BioWa's Potelligent® Technology For Use In Antibody Research And Development PDF file:New window opens

January 9, 2007

BioWa And Medarex Announce Allowance Of Investigational New Drug Application For Second-Generation Anti-Cd30 Antibody (Mdx-1401) Enhanced Using Potelligent® Technology PDF file:New window opens

Back to top

Copyright © BioWa, Inc. All rights reserved.